IP Library Granted Patent US 9,707,177
Granted Patent B2
US 9,707,177 · App. 14/259,010 · Granted Jul 18, 2017

Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same

Inventor: Zahra Mansouri (Tahoe City, CA)
Assignee: Laboratory Skin Care, Inc.
A61K9/1611A61K9/0014A61K9/10A61K9/14A61K9/1694A61K31/235A61K31/353A61K31/355A61K31/525A61K31/60A61K38/385A61K38/40A61K47/48853A61K47/48861Y10T428/2982
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,707,177
App. No.
14/259,010
Granted
Jul 18, 2017
Kind
B2
Abstract

Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications.

Claims (15)

1. A method of delivering an active agent to a subject, the method comprising:

applying a composition comprising:

spherical nanoporous calcium phosphate particles, wherein the particles are complexed with an active agent and 60 % or more of the particles in the composition have a diameter ranging from 0.1 μm to 2 μm;

to a topical region of the subject to deliver the active agent to the subject.

2. The method according to claim 1 , wherein the particles have a porosity ranging from 30 % to 85 % as determined by ASTM D 4284-88.

3. The method according to claim 2 , wherein the particles have a pore size ranging from 2 nm to 100 nm.

4. The method according to claim 1 , wherein the amount of active agent complexed with the particles ranges from 0.01 mg to 300 mg active agent per gram of particles.

5. The method according to claim 1 , wherein the topical region is a mucosal location.

6. The method according to claim 1 , wherein the topical region is a keratinized skin surface.

7. The method according to claim 6 , wherein the method is a method of delivering the active agent at least into the stratum corneum of the subject.

8. The method according to claim 6 , wherein the method is a method of delivering the active agent into the deep stratum corneum of the subject.

9. The method according to claim 6 , wherein the method is a method of delivering the active agent through the stratum corneum.

10. The method according to claim 6 , wherein the method is a method of delivering the active agent into the dermis of the subject.

11. The method according to claim 6 , wherein the method is a method of systemically delivering the active agent to the subject.

12. The method according to claim 1 , wherein 75% or more of the particles in the composition have a diameter ranging from 0.1 μm to 2 μm.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 033307 FRAME: 0107. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 12, 2014
From: MANSOURI, ZAHRA
To: LABORATORY SKIN CARE, INC.
Reel/Frame 033521/0574 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2014
From: MANSOURI, ZAHRA
To: LABORATORY SKIN CARE INC.
Reel/Frame 033307/0107 →
Continuity (4)
Continuation 13858677 · Apr 8, 2013
Continuation 12742235
Provisional Application 61176057 · May 6, 2009
Related Publication 20150004232A1 · Jan 1, 2015